Research ArticleNEUROPHARMACOLOGY
First Demonstration of a Functional Role for Central Nervous System Betaine/γ-Aminobutyric Acid Transporter (mGAT2) Based on Synergistic Anticonvulsant Action among Inhibitors of mGAT1 and mGAT2
H. Steve White, William P. Watson, Suzanne L. Hansen, Scott Slough, Jens Perregaard, Alan Sarup, Tina Bolvig, Gitte Petersen, Orla M. Larsson, Rasmus P. Clausen, Bente Frølund, Erik Falch, Povl Krogsgaard-Larsen and Arne Schousboe
Journal of Pharmacology and Experimental Therapeutics February 2005, 312 (2) 866-874; DOI: https://doi.org/10.1124/jpet.104.068825
H. Steve White
Anticonvulsant Drug Development Program, Department of Pharmacology and Toxicology (H.S.W.), University of Utah, Salt Lake City, Utah; Departments of Neuropharmacology (W.P.W., S.L.H., S.S.) and Medicinal Chemistry (J.P.) H. Lundbeck A/S, Valby, Denmark; and Departments of Pharmacology (A.Sa., T.B., G.P., O.M.L., A.Sc.) and Medicinal Chemistry (R.P.C., B.F., E.F., P.K.-L.), The Danish University of Pharmaceutical Sciences, Copenhagen, Denmark
William P. Watson
Anticonvulsant Drug Development Program, Department of Pharmacology and Toxicology (H.S.W.), University of Utah, Salt Lake City, Utah; Departments of Neuropharmacology (W.P.W., S.L.H., S.S.) and Medicinal Chemistry (J.P.) H. Lundbeck A/S, Valby, Denmark; and Departments of Pharmacology (A.Sa., T.B., G.P., O.M.L., A.Sc.) and Medicinal Chemistry (R.P.C., B.F., E.F., P.K.-L.), The Danish University of Pharmaceutical Sciences, Copenhagen, Denmark
Suzanne L. Hansen
Anticonvulsant Drug Development Program, Department of Pharmacology and Toxicology (H.S.W.), University of Utah, Salt Lake City, Utah; Departments of Neuropharmacology (W.P.W., S.L.H., S.S.) and Medicinal Chemistry (J.P.) H. Lundbeck A/S, Valby, Denmark; and Departments of Pharmacology (A.Sa., T.B., G.P., O.M.L., A.Sc.) and Medicinal Chemistry (R.P.C., B.F., E.F., P.K.-L.), The Danish University of Pharmaceutical Sciences, Copenhagen, Denmark
Scott Slough
Anticonvulsant Drug Development Program, Department of Pharmacology and Toxicology (H.S.W.), University of Utah, Salt Lake City, Utah; Departments of Neuropharmacology (W.P.W., S.L.H., S.S.) and Medicinal Chemistry (J.P.) H. Lundbeck A/S, Valby, Denmark; and Departments of Pharmacology (A.Sa., T.B., G.P., O.M.L., A.Sc.) and Medicinal Chemistry (R.P.C., B.F., E.F., P.K.-L.), The Danish University of Pharmaceutical Sciences, Copenhagen, Denmark
Jens Perregaard
Anticonvulsant Drug Development Program, Department of Pharmacology and Toxicology (H.S.W.), University of Utah, Salt Lake City, Utah; Departments of Neuropharmacology (W.P.W., S.L.H., S.S.) and Medicinal Chemistry (J.P.) H. Lundbeck A/S, Valby, Denmark; and Departments of Pharmacology (A.Sa., T.B., G.P., O.M.L., A.Sc.) and Medicinal Chemistry (R.P.C., B.F., E.F., P.K.-L.), The Danish University of Pharmaceutical Sciences, Copenhagen, Denmark
Alan Sarup
Anticonvulsant Drug Development Program, Department of Pharmacology and Toxicology (H.S.W.), University of Utah, Salt Lake City, Utah; Departments of Neuropharmacology (W.P.W., S.L.H., S.S.) and Medicinal Chemistry (J.P.) H. Lundbeck A/S, Valby, Denmark; and Departments of Pharmacology (A.Sa., T.B., G.P., O.M.L., A.Sc.) and Medicinal Chemistry (R.P.C., B.F., E.F., P.K.-L.), The Danish University of Pharmaceutical Sciences, Copenhagen, Denmark
Tina Bolvig
Anticonvulsant Drug Development Program, Department of Pharmacology and Toxicology (H.S.W.), University of Utah, Salt Lake City, Utah; Departments of Neuropharmacology (W.P.W., S.L.H., S.S.) and Medicinal Chemistry (J.P.) H. Lundbeck A/S, Valby, Denmark; and Departments of Pharmacology (A.Sa., T.B., G.P., O.M.L., A.Sc.) and Medicinal Chemistry (R.P.C., B.F., E.F., P.K.-L.), The Danish University of Pharmaceutical Sciences, Copenhagen, Denmark
Gitte Petersen
Anticonvulsant Drug Development Program, Department of Pharmacology and Toxicology (H.S.W.), University of Utah, Salt Lake City, Utah; Departments of Neuropharmacology (W.P.W., S.L.H., S.S.) and Medicinal Chemistry (J.P.) H. Lundbeck A/S, Valby, Denmark; and Departments of Pharmacology (A.Sa., T.B., G.P., O.M.L., A.Sc.) and Medicinal Chemistry (R.P.C., B.F., E.F., P.K.-L.), The Danish University of Pharmaceutical Sciences, Copenhagen, Denmark
Orla M. Larsson
Anticonvulsant Drug Development Program, Department of Pharmacology and Toxicology (H.S.W.), University of Utah, Salt Lake City, Utah; Departments of Neuropharmacology (W.P.W., S.L.H., S.S.) and Medicinal Chemistry (J.P.) H. Lundbeck A/S, Valby, Denmark; and Departments of Pharmacology (A.Sa., T.B., G.P., O.M.L., A.Sc.) and Medicinal Chemistry (R.P.C., B.F., E.F., P.K.-L.), The Danish University of Pharmaceutical Sciences, Copenhagen, Denmark
Rasmus P. Clausen
Anticonvulsant Drug Development Program, Department of Pharmacology and Toxicology (H.S.W.), University of Utah, Salt Lake City, Utah; Departments of Neuropharmacology (W.P.W., S.L.H., S.S.) and Medicinal Chemistry (J.P.) H. Lundbeck A/S, Valby, Denmark; and Departments of Pharmacology (A.Sa., T.B., G.P., O.M.L., A.Sc.) and Medicinal Chemistry (R.P.C., B.F., E.F., P.K.-L.), The Danish University of Pharmaceutical Sciences, Copenhagen, Denmark
Bente Frølund
Anticonvulsant Drug Development Program, Department of Pharmacology and Toxicology (H.S.W.), University of Utah, Salt Lake City, Utah; Departments of Neuropharmacology (W.P.W., S.L.H., S.S.) and Medicinal Chemistry (J.P.) H. Lundbeck A/S, Valby, Denmark; and Departments of Pharmacology (A.Sa., T.B., G.P., O.M.L., A.Sc.) and Medicinal Chemistry (R.P.C., B.F., E.F., P.K.-L.), The Danish University of Pharmaceutical Sciences, Copenhagen, Denmark
Erik Falch
Anticonvulsant Drug Development Program, Department of Pharmacology and Toxicology (H.S.W.), University of Utah, Salt Lake City, Utah; Departments of Neuropharmacology (W.P.W., S.L.H., S.S.) and Medicinal Chemistry (J.P.) H. Lundbeck A/S, Valby, Denmark; and Departments of Pharmacology (A.Sa., T.B., G.P., O.M.L., A.Sc.) and Medicinal Chemistry (R.P.C., B.F., E.F., P.K.-L.), The Danish University of Pharmaceutical Sciences, Copenhagen, Denmark
Povl Krogsgaard-Larsen
Anticonvulsant Drug Development Program, Department of Pharmacology and Toxicology (H.S.W.), University of Utah, Salt Lake City, Utah; Departments of Neuropharmacology (W.P.W., S.L.H., S.S.) and Medicinal Chemistry (J.P.) H. Lundbeck A/S, Valby, Denmark; and Departments of Pharmacology (A.Sa., T.B., G.P., O.M.L., A.Sc.) and Medicinal Chemistry (R.P.C., B.F., E.F., P.K.-L.), The Danish University of Pharmaceutical Sciences, Copenhagen, Denmark
Arne Schousboe
Anticonvulsant Drug Development Program, Department of Pharmacology and Toxicology (H.S.W.), University of Utah, Salt Lake City, Utah; Departments of Neuropharmacology (W.P.W., S.L.H., S.S.) and Medicinal Chemistry (J.P.) H. Lundbeck A/S, Valby, Denmark; and Departments of Pharmacology (A.Sa., T.B., G.P., O.M.L., A.Sc.) and Medicinal Chemistry (R.P.C., B.F., E.F., P.K.-L.), The Danish University of Pharmaceutical Sciences, Copenhagen, Denmark
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleNEUROPHARMACOLOGY
First Demonstration of a Functional Role for Central Nervous System Betaine/γ-Aminobutyric Acid Transporter (mGAT2) Based on Synergistic Anticonvulsant Action among Inhibitors of mGAT1 and mGAT2
H. Steve White, William P. Watson, Suzanne L. Hansen, Scott Slough, Jens Perregaard, Alan Sarup, Tina Bolvig, Gitte Petersen, Orla M. Larsson, Rasmus P. Clausen, Bente Frølund, Erik Falch, Povl Krogsgaard-Larsen and Arne Schousboe
Journal of Pharmacology and Experimental Therapeutics February 1, 2005, 312 (2) 866-874; DOI: https://doi.org/10.1124/jpet.104.068825
Research ArticleNEUROPHARMACOLOGY
First Demonstration of a Functional Role for Central Nervous System Betaine/γ-Aminobutyric Acid Transporter (mGAT2) Based on Synergistic Anticonvulsant Action among Inhibitors of mGAT1 and mGAT2
H. Steve White, William P. Watson, Suzanne L. Hansen, Scott Slough, Jens Perregaard, Alan Sarup, Tina Bolvig, Gitte Petersen, Orla M. Larsson, Rasmus P. Clausen, Bente Frølund, Erik Falch, Povl Krogsgaard-Larsen and Arne Schousboe
Journal of Pharmacology and Experimental Therapeutics February 1, 2005, 312 (2) 866-874; DOI: https://doi.org/10.1124/jpet.104.068825
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement